BCT-HA Kit for Dehydrated and Wrinkled Skin

Early Phase 1

Completed

• Conditions: Rhytides; Wrinkle
• Interventions: Device: Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3); Other: PRP Only; Other: Placebo

• Registration Number: NCT05514834
• Lead Sponsor: University of Minnesota

Brief Summary

This study will assess the efficacy of Cellular MatrixTM BCT-HA Kit treatment compared to placebo condition on revitalization and skin rejuvenation on the midface. Particular attention will be made to the safety aspects, as well as the histological consequences of treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-10
• Study First Submitted: 2022-07-25
• Study First Submitted QC: 2022-08-23
• Study First Posted: 2022-08-24
• Primary Completion: 2023-10-01
• Study Completion: 2024-02-29
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-26
• Last Update Posted: 2024-04-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Subjects who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained including HIPPA Authorization
• Healthy men and women, ages 30 - 65 years of age
• Subjects with Fitzpatrick photo skin type I-VI
• Subjects with moderate to severe nasolabial folds contour deficiencies or other facial wrinkles. Degree of nasolabial folds or other facial wrinkles will be determined on the basis of the Wrinkles Severity Rating Scale
• Subjects who agree not to have any other procedures of affecting skin quality (microdermabrasion, peels, acne treatments, toxin, fillers etc.) for the duration of the study
• Subjects who understand the study and are able to follow study instructions and are willing to attend the required study visits.
• Subjects who agree to be photographed for research purposes and their identity may not be concealed in these photographs.

Exclusion Criteria

• Subjects who have had any kind of aesthetic therapy (peeling, laser, ultrasound, toxins, fillers) in the facial area during the last 6 months
• Presence of implant in the facial area to treat
• Contraindications to the use of antiseptics (Biseptine, Amukine)
• Subjects who have an active or known skin inflammation or infection within the treatment area.
• Subjects who have an active or known acute skin allergies
• Subjects who have a known allergy to hyaluronic acid
• Subjects who have any other dermatologic conditions including acne, rosacea, eczema, psoriasis, actinic keratosis, severe sun damage, infection, or scars within the treatment area.
• Subjects of child-bearing potential who are not using an approved method of birth control (oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as post-menopausal (absence of menstrual bleeding for one year), hysterectomy, or bilateral oophorectomy.
• Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy.
• Subjects who have been diagnosed with diabetes
• Subjects who are Immunosuppressed
• Subjects who are HIV+ / VHB+ / VHC+
• Subjects who have had/will have a COVID vaccine within 2 weeks of study participation
• Subjects who have had/will have a dental procedure within 4 weeks of study participation
• Subjects with a history of severe bee allergy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
combined HA with PRP	Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)	Hyaluronic acid and PRP combination treatment
PRP	PRP Only	Platelet rich plasma without hyaluronic acid
Placebo	Placebo	saline solution

Primary Outcome Measures

Name	Time	Method
Visual Analog Score for patients	Immediately after 1st, 2nd and 3rd treatments	Visual analog rating of pain associated with treatment administration ranging between 0 and 10, pain scale.
Change in Skin Quality Rating Scale	Week 32	Skin Quality Rating Scale is a 10 point scales used to assess skin quality, including radiance, smoothness, pigmentation, erythema, and pore size.
Change in FACE-Q Score	Week 32	The following eight FACE-Q scales: (1) satisfaction with overall facial appearance (measures patient satisfaction with the overall appearance of their face); (2) satisfaction with decision (measures patient satisfaction with their decision to undergo the procedure;(3) cheekbones; (4) chin; (5) cheeks; (6) lower face; (7) jawline; and (8) nasolabial folds (items 3 through 8 measure overall and area-specific appearance appraisal to evaluate satisfaction with specific facial areas). Higher FACE-Q scores indicate superior satisfaction
Change in Global Aesthetic Improvement Scale	Week 32	This is a 7 point scale to assess degree of improvement of facial skin after treatment.
Physician's Global assessment to measure quality of life	4 weeks after treatment 1st, 2nd and 3rd treatments and 32 weeks after enrollment	Patient rating of improvement in treated area ranging from 1 to 5, with 5 being worse.
Wrinkle assessment	Week 32	Wrinkle Assessment Score is a 9 point scale to asses severity of wrinkles.

Trial Locations

Locations (1)

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States